Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.37 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21667967 | 0.90 | LTA4H (0.43) | HRH3LTA4HMAOB | |
| SCHEMBL21667821 | 0.88 | LTA4H (0.45) | ALDH1A1HRH3LTA4HMAOB | |
| SCHEMBL21941329 | 0.85 | HRH3 (0.43) | KDM4EALDH1A1HRH3SMN1; SMN2MAOB | |
| SCHEMBL19669285 | 0.85 | ALDH1A1 (0.45) | KDM4EALDH1A1HRH3SMN1; SMN2LMNA | |
| SCHEMBL29307669 | 0.84 | HRH3 (0.44) | HRH3MAOBPSMB1PSMB5PSMB2 | |
| SCHEMBL21743241 | 0.83 | HRH3 (0.39) | KDM4EALDH1A1HRH3SMN1; SMN2LTA4H | |
| SCHEMBL10223194 | 0.79 | KDM4E (0.43) | KDM4EALDH1A1HRH3SMN1; SMN2MAOB | |
| SCHEMBL12331214 | 0.78 | — | — | |
| SCHEMBL18650122 | 0.77 | PSMB1 (0.45) | KDM4EALDH1A1HRH3SMN1; SMN2MAOB | |
| SCHEMBL18403142 | 0.77 | ALDH1A1 (0.40) | KDM4EALDH1A1HRH3LTA4HHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200039961-A1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | Epizyme, Inc. | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039961-A1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | SHMT1, BHMT, EHMT2 | KDM4E 292/4885ALDH1A1 282/4885HRH3 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.